文献速递类风湿关节炎

类风湿关节炎患者亚组中持续性无DMARD缓解:两项早期关节炎前瞻性队列分析

Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis.
PubMed 文献 · Lancet Rheumatol · 2024-12-20

本研究利用Leiden早期关节炎门诊(EAC)和Rotterdam早期关节炎队列(tREACH)两项前瞻性随访数据,比较5年(EAC)或3年内(tREACH)是否使用生物制剂DMARD的患者达到持续性无DMARD缓解的比例。结果显示使用生物制剂DMARD者无一达到持续性无DMARD缓解,而未使用者中EAC有37%、tREACH有15%达到该终点;作者认为现行EULAR不推荐完全停用DMARD的建议可能受确认偏倚影响。

要点

  • 使用生物制剂DMARD的患者中无一达到持续性无DMARD缓解。
  • 未使用生物制剂DMARD者中,EAC队列37%、tREACH队列15%达到持续性无DMARD缓解。
  • 作者认为现行EULAR不推荐停用DMARD的建议可能受确认偏倚影响。

核心结论

  • 对于需要生物制剂DMARD的类风湿关节炎患者亚组,持续性无DMARD缓解似乎不可达到。
  • 对于不需要生物制剂DMARD的类风湿关节炎患者,无DMARD缓解是可达到的。
  • 作者认为现行EULAR不推荐停用DMARD的建议可能受确认偏倚影响,并认为未来的DMARD停用建议应予以修订。

研究设计与样本

  • 研究使用Leiden早期关节炎门诊(EAC)和Rotterdam早期关节炎队列(tREACH)两项前瞻性随访的早期类风湿关节炎患者人群数据。
  • tREACH是一项以达标治疗为导向的试验,患者在對三联DMARD治疗(甲氨蝶呤、柳氮磺吡啶和羟氯喹)反应不足时开始使用生物制剂DMARD。
  • 患者伙伴参与了EAC和tREACH两项研究的设计。
  • 主要结局为持续性无DMARD缓解,定义为停用DMARD后至少1年无临床滑膜炎。
  • 采用Kaplan-Meier曲线比较5年(EAC)或3年(tREACH)内是否使用生物制剂DMARD的患者。

主要发现

  • EAC队列纳入627例患者,其中女性391例(62%)、男性236例(38%),平均年龄60岁(SD 14),529例患者中502例(95%)为白人。
  • EAC队列中89例(14%)曾使用生物制剂DMARD,538例(86%)从未使用生物制剂DMARD。
  • EAC队列中使用生物制剂DMARD的患者无一达到持续性无DMARD缓解,而未使用者5年时37%达到持续性无DMARD缓解(HR 0.02,95%CI 0.00-0.10;p<0.0001)。
  • tREACH队列纳入425例患者,其中女性286例(67%)、男性139例(33%),平均年龄54岁(SD 14),未记录族裔数据。
  • tREACH队列中154例(36%)曾使用生物制剂DMARD,271例(64%)从未使用生物制剂DMARD;使用生物制剂DMARD者无一达到持续性无DMARD缓解,而未使用者3年时15%达到持续性无DMARD缓解(HR 0.03,95%CI 0.00-0.21;p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为现行EULAR不推荐停用DMARD的建议可能受确认偏倚影响,并认为未来的DMARD停用建议应予以修订。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: About 20% of patients with rheumatoid arthritis on disease-modifying antirheumatic drugs (DMARDs) can reach sustained DMARD-free remission. Nonetheless, the 2022 EULAR recommendations discourage complete cessation of DMARDs due to flare risk. The evidence behind this recommendation is obtained from trial populations using biological DMARDs, representing only a subgroup of the total population of patients with rheumatoid arthritis. We hypothesised that patients requiring biological DMARDs represent a subgroup that is less capable of reaching sustained DMARD-free remission compared with patients not requiring a biological DMARD. METHODS: In this study we used data from two prospectively followed up populations of patients with early rheumatoid arthritis, the Leiden Early Arthritis Clinic (EAC) and the treatment in the Rotterdam Early Arthritis Cohort (tREACH), a treat-to-target steered trial in which biological DMARDs were started when patients had inadequate response to triple DMARD-therapy (methotrexate, sulfasalazine, and hydroxychloroquine). Patient partners were involved in the design of both the EAC and tREACH. The primary outcome was sustained DMARD-free remission, which was defined as absence of clinical synovitis after discontinuation of DMARDs for at least 1 year. Patients who did or did not receive biological DMARDs in 5 years (EAC) or 3 years (tREACH) were compared using Kaplan-Meier curves. FINDINGS: 627 patients from the EAC were included, of whom 391 (62%) were female and 236 (38%) were male. The mean age was 60 years (SD 14) and 502 (95%) of 529 patients were White. 89 (14%) of 627 patients had ever used a biological DMARD and 538 (86%) had never used a biological DMARD. None of the patients that used a biological DMARD reached sustained DMARD-free remission, whereas 37% of the patients who never used a biological DMARD reached sustained DMARD-free remission at 5 years (hazard ratio [HR] 0·02, 95% CI 0·00-0·10; p<0·0001). From the tREACH population, 425 patients were included in the study. 286 (67%) patients were female, 139 (33%) were male, and the mean age was 54 years (SD 14); ethnicity data not recorded. 154 (36%) of 425 patients had ever used a biological DMARD and 271 (64%) had never used a biological DMARD during follow-up. None of the patients that used a biological DMARD reached sustained DMARD-free remission, whereas 15% of patients who never used a biological DMARD reached sustained DMARD-free remission at 3 years (HR 0·03, 95% CI 0·00-0·21; p<0·0001). INTERPRETATION: For the subgroup of patients with rheumatoid arthritis who require biological DMARDs, sustained DMARD-free remission does not seem attainable. In contrast, in patients with rheumatoid arthritis who do not require biological DMARDs, DMARD-free remission is attainable. These data suggest that the current EULAR recommendation to not stop DMARD use might suffer from ascertainment bias. Future recommendations about DMARD cessation should be amended. FUNDING: The Dutch Arthritis Foundation and the European Research Council.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Heutz JW, de Jong PHP, Verstappen M, et al. Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis. Lancet Rheumatol. 2024. PMID: 39718182. doi:10.1016/S2665-9913(24)00234-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。